Small Lymphocytic Lymphoma Clinical Trials

86 recruitingLast updated: July 17, 2026

There are 86 actively recruiting small lymphocytic lymphoma clinical trials across 46 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1. Top locations include Boston, Massachusetts, United States, Columbus, Ohio, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Small Lymphocytic Lymphoma Trials at a Glance

86 actively recruiting trials for small lymphocytic lymphoma are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Phase 2 with 48 trials, with the heaviest enrollment activity in Boston, Columbus, and Houston. Lead sponsors running small lymphocytic lymphoma studies include Mayo Clinic, Fred Hutchinson Cancer Center, and BeOne Medicines.

Browse small lymphocytic lymphoma trials by phase

Treatments under study

About Small Lymphocytic Lymphoma Clinical Trials

Looking for clinical trials for Small Lymphocytic Lymphoma? There are currently 49 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Small Lymphocytic Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Small Lymphocytic Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 86 trials

Recruiting
Phase 2

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more
M.D. Anderson Cancer Center168 enrolled1 locationNCT04169737
Recruiting
Phase 1Phase 2

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Acute Lymphoblastic LeukemiaSmall Lymphocytic LymphomaLymphoblastic Lymphoma+4 more
National Cancer Institute (NCI)132 enrolled1 locationNCT06364423
Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma+2 more
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00923507
Recruiting

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Canadian Cancer Trials Group247 enrolled6 locationsNCT05371808
Recruiting
Phase 2

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center20 enrolled1 locationNCT07194980
Recruiting
Phase 3

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines500 enrolled186 locationsNCT06973187
Recruiting
Phase 3

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
National Cancer Institute (NCI)247 enrolled631 locationsNCT04269902
Recruiting
Phase 3

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
AstraZeneca420 enrolled30 locationsNCT07509151
Recruiting
Phase 3

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Merck Sharp & Dohme LLC1,200 enrolled200 locationsNCT06136559
Recruiting
Phase 3

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled187 locationsNCT06943872
Recruiting
Phase 2

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Small Lymphocytic LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC320 enrolled74 locationsNCT05963074
Recruiting
Phase 2

Allo HSCT Using RIC and PTCy for Hematological Diseases

Acute Myelogenous LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid+15 more
Masonic Cancer Center, University of Minnesota56 enrolled1 locationNCT05805605
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled175 locationsNCT01804686
Recruiting
Phase 2

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AstraZeneca80 enrolled36 locationsNCT07024706
Recruiting
Phase 1

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Hoffmann-La Roche332 enrolled31 locationsNCT05091424
Recruiting
Phase 2

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.100 enrolled32 locationsNCT07221500
Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Not Applicable

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Chronic Lymphocytic LeukemiaLymphomaFollicular Lymphoma+6 more
UNC Lineberger Comprehensive Cancer Center40 enrolled1 locationNCT06860880
Recruiting
Phase 2

Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jennifer Woyach50 enrolled1 locationNCT07685717
Recruiting
Phase 2

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Mayo Clinic120 enrolled3 locationsNCT03516617